These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35560019)

  • 1. Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.
    Chan ML; Shiu SW; Cheung CL; Yu-Hung Leung A; Tan KC
    Endocr Connect; 2022 Jun; 11(6):. PubMed ID: 35560019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B; Wu M; Cao A; Li H; Liu J
    Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
    Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P
    Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S; Vaziri ND
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor.
    Sorrentino V; Zelcer N
    Curr Opin Lipidol; 2012 Jun; 23(3):213-219. PubMed ID: 22510808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia.
    Zhang CP; Tian Y; Zhang M; Tuo QH; Chen JX; Liao DF
    Med Hypotheses; 2016 Jan; 86():138-42. PubMed ID: 26601593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of intestinal LDLR by the LXR-IDOL axis.
    van Loon NM; van Wouw SAE; Ottenhoff R; Nelson JK; Kingma J; Scheij S; Moeton M; Zelcer N
    Atherosclerosis; 2020 Dec; 315():1-9. PubMed ID: 33190106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
    Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
    Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia.
    Yu Q; Zheng H; Zhang Y
    Vascul Pharmacol; 2021 Oct; 140():106878. PubMed ID: 34015522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation.
    Sorrentino V; Nelson JK; Maspero E; Marques ARA; Scheer L; Polo S; Zelcer N
    J Lipid Res; 2013 Aug; 54(8):2174-2184. PubMed ID: 23733886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia.
    Liang C; Wang X; Peng K; Lai P; Liu Z; Ma J; Chen X; Liu G; Zheng M; Wang Y; Yang H; Liu G; Xian X; Gao M
    Oxid Med Cell Longev; 2022; 2022():1889632. PubMed ID: 35656026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
    Zhang L; Reue K; Fong LG; Young SG; Tontonoz P
    Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2541-6. PubMed ID: 22936343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells.
    Huang Y; Ning K; Li WW; Lin G; Hou CL; Wang MJ; Zhu YC
    Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1082-C1096. PubMed ID: 32938225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9.
    Gu HM; Zhang DW
    J Biomed Res; 2015 Sep; 29(5):356-61. PubMed ID: 26445568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
    Ishibashi M; Masson D; Westerterp M; Wang N; Sayers S; Li R; Welch CL; Tall AR
    J Lipid Res; 2010 Sep; 51(9):2655-63. PubMed ID: 20562239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
    Hong C; Duit S; Jalonen P; Out R; Scheer L; Sorrentino V; Boyadjian R; Rodenburg KW; Foley E; Korhonen L; Lindholm D; Nimpf J; van Berkel TJ; Tontonoz P; Zelcer N
    J Biol Chem; 2010 Jun; 285(26):19720-6. PubMed ID: 20427281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL).
    Sorrentino V; Scheer L; Santos A; Reits E; Bleijlevens B; Zelcer N
    J Biol Chem; 2011 Aug; 286(34):30190-9. PubMed ID: 21734303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Di-(2-ethylhexyl) Phthalate Limits the Lipid-Lowering Effects of Simvastatin by Promoting Protein Degradation of Low-Density Lipoprotein Receptor: Role of PPARγ-PCSK9 and LXRα-IDOL Signaling Pathways.
    Guo BC; Kuo KL; Huang JW; Chen CH; Tarng DC; Lee TS
    Antioxidants (Basel); 2023 Feb; 12(2):. PubMed ID: 36830035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.